fda glp-1 enforcement news warns Novo Nordisk of unreported side effects FDA is moving to restrict
Description
Through December 31, 2026, Novo Nordisk is offering eligible self-pay patients new to Wegovy injectables an introductory price of $199 per fill for the first two fills of medication (0.25 mg and 0.5 mg doses only)
CVOT, cardiovascular outcome trial
See the related article at Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake
A meta-analysis also reported diagnoses of medullary thyroid carcinoma in patients taking GLP-1RAs, reinforcing the at-risk status as a contraindication to GLP-1RA treatment
